Bellicum Pharmaceuticals (NASDAQ:BLCM) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Bellicum Pharmaceuticals (NASDAQ:BLCMGet Rating) in a research note released on Monday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Bellicum Pharmaceuticals Stock Performance

Shares of BLCM stock opened at $1.03 on Monday. The stock has a market capitalization of $8.89 million, a P/E ratio of -2.06 and a beta of 1.25. Bellicum Pharmaceuticals has a fifty-two week low of $0.93 and a fifty-two week high of $2.20. The company has a 50 day moving average price of $1.10 and a 200 day moving average price of $1.23.

About Bellicum Pharmaceuticals

(Get Rating)

Bellicum Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens.

Read More

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.